DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech ...
As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired ...
ICON’s ICLR focus on Patient Access & Engagement strategy is a major tailwind along with partnerships and acquisitions. The stock carries a Zacks Rank #2 (Buy) currently. ICON is gaining from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results